Serious haematological toxicity during and after ipilimumab treatment: a case series
Open Access
- 1 July 2014
- journal article
- case report
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 8 (1) , 240
Abstract
Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab has been shown to improve overall survival in previously treated and treatment-naïve patients with unresectable stage III or IV melanoma. Consistent with its proposed immunomodulating mechanism of action, the most common toxicities associated with ipilimumab therapy are immune-related in nature and include those related to the skin and gastrointestinal tract, with endocrine and hepatic events also frequent. Other rare adverse events, including haematological aberrations, may also occur and can have serious consequences if unrecognised. Here we describe three patients who developed serious haematological adverse events during or after treatment with ipilimumab.Keywords
This publication has 12 references indexed in Scilit:
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumabCancer, 2013
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanomaExperimental Hematology & Oncology, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trialsJournal of Clinical Oncology, 2009
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)Journal of Immunotherapy, 2009
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaCancer Immunology, Immunotherapy, 2008